TW202523669A - 用於製備選擇性雌激素受體降解劑之方法 - Google Patents
用於製備選擇性雌激素受體降解劑之方法 Download PDFInfo
- Publication number
- TW202523669A TW202523669A TW113140271A TW113140271A TW202523669A TW 202523669 A TW202523669 A TW 202523669A TW 113140271 A TW113140271 A TW 113140271A TW 113140271 A TW113140271 A TW 113140271A TW 202523669 A TW202523669 A TW 202523669A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- formula
- phenyl
- trifluoromethyl
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/44—Palladium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263305520P | 2022-02-01 | 2022-02-01 | |
| US63/305,520 | 2022-02-01 | ||
| US202263409060P | 2022-09-22 | 2022-09-22 | |
| US63/409,060 | 2022-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202523669A true TW202523669A (zh) | 2025-06-16 |
Family
ID=85382684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113140271A TW202523669A (zh) | 2022-02-01 | 2023-02-01 | 用於製備選擇性雌激素受體降解劑之方法 |
| TW112103450A TWI863110B (zh) | 2022-02-01 | 2023-02-01 | 用於製備選擇性雌激素受體降解劑之方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112103450A TWI863110B (zh) | 2022-02-01 | 2023-02-01 | 用於製備選擇性雌激素受體降解劑之方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11926634B2 (https=) |
| EP (1) | EP4472982A1 (https=) |
| JP (3) | JP7387926B2 (https=) |
| KR (2) | KR20250006312A (https=) |
| AU (2) | AU2023216654B2 (https=) |
| CA (1) | CA3243621A1 (https=) |
| CO (1) | CO2024009411A2 (https=) |
| CR (1) | CR20240283A (https=) |
| DO (1) | DOP2024000150A (https=) |
| IL (1) | IL313886A (https=) |
| JO (1) | JOP20240169A1 (https=) |
| MX (1) | MX2024009453A (https=) |
| PE (1) | PE20241731A1 (https=) |
| TW (2) | TW202523669A (https=) |
| WO (1) | WO2023150056A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020137965A (ja) * | 2019-03-01 | 2020-09-03 | 株式会社三洋物産 | 遊技機 |
| US20240199629A1 (en) * | 2022-02-01 | 2024-06-20 | Eli Lilly And Company | Processes for the preparation of selective estrogen receptor degraders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100849559B1 (ko) | 2004-01-22 | 2008-07-31 | 일라이 릴리 앤드 캄파니 | 혈관운동 증상의 치료를 위한 선택적 에스트로겐 수용체조절제 |
| US20080221163A1 (en) | 2005-01-18 | 2008-09-11 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
| EP2343287A1 (en) | 2009-12-10 | 2011-07-13 | Almirall, S.A. | New 2-aminothiadiazole derivatives |
| AU2012257802A1 (en) | 2011-05-17 | 2013-10-31 | F. Hoffmann-La Roche Ag | Inhibitors of Bruton's tyrosine kinase |
| CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| WO2016097071A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
| CN112424205B (zh) | 2018-07-12 | 2023-10-31 | 伊莱利利公司 | 选择性的雌激素受体降解剂 |
| TWI702219B (zh) | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| KR20220046586A (ko) | 2019-07-22 | 2022-04-14 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 선택적 에스트로겐 수용체 분해제 |
| CA3169679A1 (en) | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| WO2021191378A1 (en) * | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer |
| AR123185A1 (es) * | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
| TWI837605B (zh) | 2021-03-09 | 2024-04-01 | 美商美國禮來大藥廠 | 使用serd組合給藥方案治療癌症之方法 |
| TWI894443B (zh) | 2021-03-16 | 2025-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
-
2023
- 2023-01-27 CA CA3243621A patent/CA3243621A1/en active Pending
- 2023-01-27 CR CR20240283A patent/CR20240283A/es unknown
- 2023-01-27 KR KR1020247041076A patent/KR20250006312A/ko active Pending
- 2023-01-27 WO PCT/US2023/011671 patent/WO2023150056A1/en not_active Ceased
- 2023-01-27 PE PE2024001567A patent/PE20241731A1/es unknown
- 2023-01-27 IL IL313886A patent/IL313886A/en unknown
- 2023-01-27 AU AU2023216654A patent/AU2023216654B2/en active Active
- 2023-01-27 EP EP23707540.3A patent/EP4472982A1/en active Pending
- 2023-01-27 KR KR1020247028876A patent/KR102743629B1/ko active Active
- 2023-01-27 US US18/160,457 patent/US11926634B2/en active Active
- 2023-01-27 MX MX2024009453A patent/MX2024009453A/es unknown
- 2023-02-01 JP JP2023013779A patent/JP7387926B2/ja active Active
- 2023-02-01 TW TW113140271A patent/TW202523669A/zh unknown
- 2023-02-01 TW TW112103450A patent/TWI863110B/zh active
- 2023-08-28 JP JP2023138310A patent/JP7805336B2/ja active Active
-
2024
- 2024-07-16 CO CONC2024/0009411A patent/CO2024009411A2/es unknown
- 2024-07-30 JO JOJO/P/2024/0169A patent/JOP20240169A1/ar unknown
- 2024-07-31 DO DO2024000150A patent/DOP2024000150A/es unknown
-
2025
- 2025-09-04 JP JP2025146941A patent/JP2025183283A/ja active Pending
- 2025-09-16 AU AU2025234145A patent/AU2025234145A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024009411A2 (es) | 2024-07-29 |
| KR20240135862A (ko) | 2024-09-12 |
| US20230242545A1 (en) | 2023-08-03 |
| MX2024009453A (es) | 2024-08-09 |
| JP2025183283A (ja) | 2025-12-16 |
| AU2023216654A1 (en) | 2024-07-11 |
| CR20240283A (es) | 2024-09-03 |
| AU2025234145A1 (en) | 2025-10-02 |
| US11926634B2 (en) | 2024-03-12 |
| DOP2024000150A (es) | 2024-08-30 |
| IL313886A (en) | 2024-08-01 |
| WO2023150056A1 (en) | 2023-08-10 |
| TW202346300A (zh) | 2023-12-01 |
| JP7387926B2 (ja) | 2023-11-28 |
| KR102743629B1 (ko) | 2024-12-17 |
| AU2023216654B2 (en) | 2025-09-25 |
| CA3243621A1 (en) | 2023-08-10 |
| KR20250006312A (ko) | 2025-01-10 |
| JP2023112696A (ja) | 2023-08-14 |
| TWI863110B (zh) | 2024-11-21 |
| JOP20240169A1 (ar) | 2024-07-30 |
| PE20241731A1 (es) | 2024-08-19 |
| JP7805336B2 (ja) | 2026-01-23 |
| JP2023162334A (ja) | 2023-11-08 |
| EP4472982A1 (en) | 2024-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025183283A (ja) | 選択的エストロゲン受容体分解剤の調製のためのプロセス | |
| CN110041333B (zh) | 溴结构域抑制剂化合物及其用途 | |
| CN102482221B (zh) | 作为katii抑制剂的双环和三环化合物 | |
| EP3898581B1 (en) | Substituted heterocycle fused gamma-carbolines synthesis | |
| JP2022513934A (ja) | 置換複素環縮合γ－カルボリンの合成 | |
| JP7347852B2 (ja) | 重水素化大環状化合物の調製方法 | |
| EP3377480A1 (en) | 4-((6-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation | |
| CN107176955A (zh) | 一种巴瑞替尼的制备方法 | |
| JP6332818B2 (ja) | チカグレロルの中間体およびその製造法、およびチカグレロルの製造法 | |
| CN107548393B (zh) | 适用于治疗癌症的1-(环)烷基吡啶-2-酮的三环稠合衍生物 | |
| KR101357392B1 (ko) | 합성 중간체로서의 티아졸릴-피라졸로피리미딘 화합물 및 관련 합성 방법 | |
| US20240199629A1 (en) | Processes for the preparation of selective estrogen receptor degraders | |
| CN117677616A (zh) | 制备血红蛋白调节剂的方法 | |
| BR112024013443B1 (pt) | Processos para a preparação de degradadores seletivos de receptores de estrogênio | |
| BR122025017409A2 (pt) | Compostos degradadores seletivos de receptores de estrogênio | |
| CN102216274A (zh) | (R)-3-(2,3-二羟基丙基)-6-氟-5-(2-氟-4-碘苯基氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮及其中间体的制备方法 | |
| BR122025017416A2 (pt) | Compostos degradadores seletivos de receptores de estrogênio | |
| CN118647619A (zh) | 选择性雌激素受体降解剂的制备方法 | |
| JP6375374B2 (ja) | ピリミジン中間体の製造方法 | |
| AU2013363731B2 (en) | An improved process for making zilpaterol | |
| TW202527939A (zh) | 單一的軸向不對稱化合物之選擇性製造方法 | |
| JP2003221394A (ja) | キヌクリジン誘導体の製造方法 | |
| KR20170044166A (ko) | 3-페닐/헤테로아릴-6-페녹시-8-알킬아미노-이미다조[1,2-ｂ]피리다진 유도체의 제조 방법 | |
| ITMI20011435A1 (it) | Procedimento per la produzione di benzossazine e nuove benzossasine |